Overview

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This is a multisite study to evaluate the efficacy, safety and plasma concentration of Nalfurafine Hydrochloride orally disintegrating tablet in the treatment of refractory pruritus in maintenance hemodialysis patients, and to bridge the efficacy data from Japan
Phase:
Phase 3
Details
Lead Sponsor:
Shenyang Sunshine Pharmaceutical Co., LTD.